Biotechnology firm Biogen is abandoning Aduhelm, its questionable Alzheimer’s drug that has floundered available on the market since its scandal-plagued regulatory approval in 2021 and brow-raising pricing.
On Wednesday, the corporate introduced it had terminated its license for Aduhelm (aducanumab) and can cease all growth and commercialization actions. The rights to Aduhelm will revert again to the Neurimmune, the Swiss biopharmaceutical firm that found it.
Biogen can even finish the Section four scientific trial, ENVISION, that was required by the Meals and Drug Administration to show Biogen’s claims that Aduhelm is efficient at slowing development of Alzheimer’s in its early phases—one thing two Section three trials did not do with certainty.
Learn 12 remaining paragraphs | Feedback